Medscape
The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically, the kinase inhibitor was approved for adults and children aged ≥ 2 years who have NF1 with symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection…
Read More
FDA Approves Mirdametinib for Neurofibromatosis Type 1
Alejandro Lupo
12:20
The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically, the kinase inhibitor was approved for adults and children aged ≥ 2 years who have NF1 with symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection…
